H.C. Wainwright analyst Arthur He downgraded BioAtla (BCAB) to Neutral from Buy without a price target The firm is awaiting clarity on the company’s pipeline development path. The firm says that with pipeline decisions pending, it is unable to project the cadence of BioAtla’s revenue at this time.